ImmunoGen Inc (IMGN):企業の財務・戦略的SWOT分析

◆英語タイトル:ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15899
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

ImmunoGen Inc (IMGN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. The company is also advancing a new class of indolino-benzodiazepine deoxy ribonucleic acid (DNA)-acting payload agents, namely IGNs. It is investigating its lead product candidate, mirvetuximab soravtansine in Phase 3 clinical trials; and combination of bevacizumab and pembrolizumab in Phase 2 clinical studies for the treatment of platinum-resistant ovarian cancer. ImmunoGen is investigating IMGN779 in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632 for the treatment of AML, and blastic plasmacytoid dendritic cell neoplasm (BPDCN). ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen Inc Key Recent Developments

Mar 01,2019 http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-top-line-results-phase-3-forward-i-study
Mar 01,2019 ImmunoGen Announces TopLine Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
Mar 01,2019 ImmunoGen struck by Phase III trial failure in ovarian cancer
Feb 27,2019 ImmunoGen announces multiple presentations at AACR Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
ImmunoGen Inc – Key Facts
ImmunoGen Inc – Key Employees
ImmunoGen Inc – Key Employee Biographies
ImmunoGen Inc – Major Products and Services
ImmunoGen Inc – History
ImmunoGen Inc – Company Statement
ImmunoGen Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
ImmunoGen Inc – Business Description
R&D Overview
ImmunoGen Inc – Corporate Strategy
ImmunoGen Inc – SWOT Analysis
SWOT Analysis – Overview
ImmunoGen Inc – Strengths
ImmunoGen Inc – Weaknesses
ImmunoGen Inc – Opportunities
ImmunoGen Inc – Threats
ImmunoGen Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
ImmunoGen Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 01, 2019: http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-top-line-results-phase-3-forward-i-study
Mar 01, 2019: ImmunoGen Announces TopLine Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
Mar 01, 2019: ImmunoGen struck by Phase III trial failure in ovarian cancer
Feb 27, 2019: ImmunoGen announces multiple presentations at AACR Annual Meeting
Feb 08, 2019: ImmunoGen reports recent progress and 2018 operating results
Jan 09, 2019: NIIMBL Announces New Projects to Advance Biopharmaceutical Manufacturing
Nov 26, 2018: ImmunoGen announces resignation of Chief Financial Officer
Nov 26, 2018: ImmunoGen announces resignation of chief financial officer
Nov 02, 2018: ImmunoGen reports recent progress and third quarter 2018 operating results
Oct 20, 2018: ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
ImmunoGen Inc, Key Facts
ImmunoGen Inc, Key Employees
ImmunoGen Inc, Key Employee Biographies
ImmunoGen Inc, Major Products and Services
ImmunoGen Inc, History
ImmunoGen Inc, Subsidiaries
ImmunoGen Inc, Key Competitors
ImmunoGen Inc, Ratios based on current share price
ImmunoGen Inc, Annual Ratios
ImmunoGen Inc, Annual Ratios (Cont...1)
ImmunoGen Inc, Interim Ratios
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
ImmunoGen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
ImmunoGen Inc, Performance Chart (2014 - 2018)
ImmunoGen Inc, Ratio Charts
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[ImmunoGen Inc (IMGN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Karyopharm Therapeutics Inc (KPTI):企業財務及び戦略的SWOT分析
    Summary Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that focuses on the discovery and development of drugs for the treatment of cancer and other diseases. The company’s lead product candidate, Selinexor, a selective inhibitor of nuclear export XPO …
  • Aeria, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Aeria, Inc. Mergers and Acquisi …
  • K3 Business Technology Group plc (KBT):企業概要、財務及び戦略的SWOT分析
    Summary K3 Business Technology Group plc (K3 Business) is an information technology service provider. The company provides computer software and consultancy services. Its products include K3 Dynamics AX, K3 Dynamics NAV, K3 Dynamics CRM, K3 SYSPRO and K3 FDS. K3 Dynamics AX is an ERP solution that s …
  • Northam Platinum Limited (NHM):企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Northam Platinum Limited" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly …
  • Morgans Hotel Group Co.:企業の戦略・SWOT・財務分析
    SummaryMorgans Hotel Group Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key …
  • Hey-Song Corporation:企業の戦略・SWOT・財務情報
    Hey-Song Corporation - Strategy, SWOT and Corporate Finance Report Summary Hey-Song Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Nonin Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Nonin Medical Inc (Nonin) is a medical device company that provides medical monitoring solutions. The company provides noninvasive physiological monitoring devices for health professionals and consumers. Its products include pulse oximeters and sensors, regional oximeters and sensors, finger …
  • St. George’s University of London:製薬・医療:M&Aディール及び事業提携情報
    Summary St. George's University of London (SGUL), a subsidiary of University of London is a medical and healthcare education provider. It offers undergraduate and post graduate courses. The university’s undergraduate courses include biomedical science BSc, healthcare practice DipHE and BSc, healthca …
  • OncoMed Pharmaceuticals Inc (OMED):企業の財務・戦略的SWOT分析
    Summary OncoMed Pharmaceuticals Inc (OncoMed) is a clinical-stage biopharmaceutical company focused on discovery and development of novel immuno-oncology (IO) therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, and anti-TI …
  • Gastar Exploration Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Gastar Exploration Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Gastar Exploration Inc (Gastar), formerly Gastar Exploration Ltd, is an energy company that offers exploration and development programs. The company explores, develops and produces natural gas …
  • PetroFrontier Corp. (PFC)(石油・ガス分野):企業M&A動向
    Summary PetroFrontier Corp. (PetroFrontier) is an oil and gas exploration company. The company explores, acquires and develops conventional and unconventional onshore petroleum and natural gas. It holds interests in four exploration permits and two exploration permit applications in the Northern Ter …
  • Wanxiang Qianchao Co., Ltd.の企業概要及び財務/SWOT分析
    Wanxiang Qianchao Co., Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and qua …
  • Valeant Pharmaceuticals International, Inc. (VRX):企業のM&A・提携動向(医療機器分野)
    Summary Valeant Pharmaceuticals International, Inc. (Valeant) is a specialty pharmaceutical company. It carries out the development, manufacture and marketing of a wide range of specialty, over-the-counter (OTC) and generic drugs. The company also offers medical contact lenses, intraocular lenses, o …
  • Martin Midstream Partners L.P.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Martin Midstream Partners L.P. …
  • United Utilities Group Plc (UU):企業の財務・戦略的SWOT分析
    United Utilities Group Plc (UU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • PATH (Program for Appropriate Technology in Health):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' PATH (Program for Appropriate T …
  • General Communication, Inc. (GNCMA):企業の財務及び戦略的SWOT分析
    Summary General Communication, Inc. (GCI) is an integrated communications provider that offers business and residential telecommunication services. The company offers products such as phones and devices. It provides services such as wireless telephone services, data services, internet access, video …
  • Covea Insurance plc:企業の戦略・SWOT・財務情報
    Covea Insurance plc - Strategy, SWOT and Corporate Finance Report Summary Covea Insurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Expres2ion Biotechnologies ApS (EXPRS2):製薬・医療:M&Aディール及び事業提携情報
    Summary Expres2ion Biotechnologies ApS (Expres2ion), a subsidiary of ExpreS2ion Biotech Holding AB is a contract research organization that offers cell lines and processes based on Drosophila S2 cells. The organization develops ExpreS2 expression system, a non-viral insect cell expression system tha …
  • Micronics, Inc. – Product Pipeline Analysis, 2016 Update
    Summary Micronics, Inc. (Micronics), a subsidiary of Sony Corporation of America is a medical device company that develops and markets in vitro diagnostic products. The company offers diagnostic products and research and development products including ABORhCard and PanNAT system. Its research and de …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆